ArticleClinical and experimental medicine2026
LncRNA SNHG25 promotes proliferation, migration, and invasion of acute myeloid leukemia by competitively binding to miR-205-5p.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a hematological malignancy, acute myeloid leukemia (AML) demonstrates considerable heterogeneity. The pathogenesis and progression are associated with aberrant long non-coding RNA (lncRNA) expression. Research indicates that lncRNA SNHG25 exerts a pro-cancerous role in various tumors, but its function in AML remains unclear. The aim was to investigate whether SNHG25 regulates AML cells function by competitive binding to miR-205-5p, thereby promoting disease progression. RT-qPCR was utilized to detect SNHG25 and miR-205-5p expression. ROC analysis was applied to evaluate diagnostic capability of SNHG25 for AML. CCK8 and Transwell assays were employed to assess proliferation, migration, and invasion of AML cells. Dual-luciferase reporter system was applied to examine interaction between SNHG25 and miR-205-5p. SNHG25 was upregulated in AML patient serum and AML cell lines. SNHG25 demonstrated a remarkable ability to distinguish AML patients from healthy controls. Overexpression of SNHG25 enhanced AML cell proliferation and accelerated migration and invasion, while silencing SNHG25 showed the opposite trend. Additionally, SNHG25 directly targets miR-205-5p, and co-suppression of SNHG25 and miR-205-5p counteracted functional consequences of silencing SNHG25 on AML cells. SNHG25 promoted malignant phenotypes of AML by adsorbing miR-205-5p, which provides a potential new target for therapy of AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.